Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04548999 (ClinicalTrials.gov)	December 3, 2020	9/9/2020	A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)	A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: Ocrelizumab;Drug: Antihistamine;Drug: Methylprednisolone	Hoffmann-La Roche	NULL	Recruiting	18 Years	55 Years	All	699	Phase 3	United States;Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Peru;Poland;Portugal;Puerto Rico;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom
2	NCT04544436 (ClinicalTrials.gov)	November 26, 2020	4/9/2020	A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)	A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: Ocrelizumab;Drug: Antihistamine;Drug: Methylprednisolone	Hoffmann-La Roche	NULL	Active, not recruiting	18 Years	55 Years	All	786	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Italy;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;Czechia;Israel;Mexico;Netherlands
3	NCT04175834 (ClinicalTrials.gov)	February 5, 2020	22/11/2019	Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab	Comparing the Risk and Severity of Infusion-Related Reactions in Patients Premedicated With Cetirizine Versus Diphenhydramine Prior to Ocrelizumab Infusions	Multiple Sclerosis;Infusion Reaction	Drug: antihistamine	Providence Health & Services	Genentech, Inc.	Active, not recruiting	18 Years	70 Years	All	52	Phase 3	United States
4	NCT02688985 (ClinicalTrials.gov)	April 29, 2016	18/2/2016	Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)	An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis	Relapsing Multiple Sclerorsis;Multiple Sclerosis, Primary Progressive	Drug: Ocrelizumab;Procedure: Lumbar Puncture;Drug: Methyloprednisolone;Drug: Antihistamine	Genentech, Inc.	NULL	Active, not recruiting	18 Years	55 Years	All	127	Phase 3	United States;Canada;Germany;Sweden
5	NCT00240032 (ClinicalTrials.gov)	October 2004	13/10/2005	A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.	A Double-Blind, Randomized, Placebo Controlled Study of An Oral Antihistamine on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone® Using Autoject® 2 for Glass Syringe.	Multiple Sclerosis	Drug: glatiramer acetate injection with oral cetirizine hydrochloride;Drug: glatiramer acetate with placebo	Teva Pharmaceutical Industries	NULL	Completed	18 Years	N/A	Both	80	Phase 4	United States

先頭へ